Iovance Biotherapeutics, Inc. (0JDK.L)
USD 3.26
(1.52%)
USD 3.26
(1.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -449.01 Million USD | -18.87% |
| 2022 | -374.75 Million USD | -14.91% |
| 2021 | -328.27 Million USD | -29.81% |
| 2020 | -250.86 Million USD | -27.41% |
| 2019 | -189.43 Million USD | -56.12% |
| 2018 | -127.3 Million USD | -38.48% |
| 2017 | -91.92 Million USD | -74.56% |
| 2016 | -43.16 Million USD | -96.05% |
| 2015 | -26.86 Million USD | -124.72% |
| 2014 | -11.95 Million USD | -99.95% |
| 2013 | -24.92 Million USD | 26.44% |
| 2012 | 508.81 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -107.81 Million USD | 3.64% |
| 2024 Q2 | -93.44 Million USD | 10.56% |
| 2023 Q2 | -102.24 Million USD | 2.77% |
| 2023 Q3 | -108.48 Million USD | -6.1% |
| 2023 Q4 | -111.54 Million USD | -2.82% |
| 2023 Q1 | -105.15 Million USD | -3.78% |
| 2023 FY | - USD | -13.15% |
| 2022 Q4 | -101.32 Million USD | -6.45% |
| 2022 Q3 | -95.19 Million USD | -0.7% |
| 2022 Q2 | -94.53 Million USD | -8.99% |
| 2022 Q1 | -86.73 Million USD | 8.59% |
| 2022 FY | - USD | -14.91% |
| 2021 Q4 | -94.88 Million USD | -18.61% |
| 2021 Q1 | -72.91 Million USD | -6.89% |
| 2021 Q2 | -80.93 Million USD | -11.01% |
| 2021 FY | - USD | -29.81% |
| 2021 Q3 | -79.99 Million USD | 1.17% |
| 2020 Q1 | -70.55 Million USD | -8.86% |
| 2020 Q3 | -58.65 Million USD | 7.43% |
| 2020 FY | - USD | -27.41% |
| 2020 Q4 | -68.21 Million USD | -16.29% |
| 2020 Q2 | -63.36 Million USD | 10.19% |
| 2019 Q2 | -49.87 Million USD | -25.58% |
| 2019 Q1 | -39.71 Million USD | -14.48% |
| 2019 FY | - USD | -56.12% |
| 2019 Q4 | -64.81 Million USD | -26.36% |
| 2019 Q3 | -51.29 Million USD | -2.85% |
| 2018 Q1 | -26.64 Million USD | -3.17% |
| 2018 Q3 | -34.8 Million USD | -11.74% |
| 2018 Q2 | -31.15 Million USD | -16.9% |
| 2018 FY | - USD | -38.48% |
| 2018 Q4 | -34.69 Million USD | 0.34% |
| 2017 Q1 | -20.66 Million USD | -236.94% |
| 2017 Q3 | -22.09 Million USD | 5.32% |
| 2017 Q4 | -25.82 Million USD | -16.89% |
| 2017 FY | - USD | -74.56% |
| 2017 Q2 | -23.33 Million USD | -12.96% |
| 2016 Q4 | -6.13 Million USD | 67.44% |
| 2016 Q1 | -6.74 Million USD | 17.5% |
| 2016 Q3 | -18.83 Million USD | -64.38% |
| 2016 FY | - USD | -96.05% |
| 2016 Q2 | -11.45 Million USD | -69.95% |
| 2015 Q4 | -8.17 Million USD | -10.76% |
| 2015 FY | - USD | -124.72% |
| 2015 Q3 | -7.37 Million USD | -18.98% |
| 2015 Q2 | -6.2 Million USD | -21.26% |
| 2015 Q1 | -5.11 Million USD | -6.45% |
| 2014 Q4 | -4.8 Million USD | -71.68% |
| 2014 FY | - USD | -99.95% |
| 2014 Q1 | -2.24 Million USD | -45.73% |
| 2014 Q2 | -2.1 Million USD | 5.97% |
| 2014 Q3 | -2.79 Million USD | -32.66% |
| 2013 Q1 | -702.95 Thousand USD | 59.16% |
| 2013 Q4 | -1.53 Million USD | 43.15% |
| 2013 Q2 | -1.02 Million USD | -46.26% |
| 2013 Q3 | -2.7 Million USD | -163.32% |
| 2013 FY | - USD | 26.44% |
| 2012 Q4 | -1.72 Million USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Imunon, Inc. | -20.78 Million USD | -2060.557% |
| Homology Medicines, Inc. | -47.75 Million USD | -840.223% |
| uniQure N.V. | -253.1 Million USD | -77.405% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -787.869% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -410.329% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | -29.974% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -387.639% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | -68.804% |
| bluebird bio, Inc. | -167.16 Million USD | -168.611% |
| Blueprint Medicines Corporation | -474.61 Million USD | 5.394% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -281.652% |
| Adicet Bio, Inc. | -136.53 Million USD | -228.863% |
| Dynavax Technologies Corporation | 9.66 Million USD | 4745.282% |
| Editas Medicine, Inc. | -163.11 Million USD | -175.271% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -199.127% |
| Geron Corporation | -174.78 Million USD | -156.899% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -332.608% |
| Illumina, Inc. | -608 Million USD | 26.149% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 113.79% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 138.573% |
| Myriad Genetics, Inc. | -67.8 Million USD | -562.261% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 207.91% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | -2.235% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 556.955% |
| Verastem, Inc. | -83.16 Million USD | -439.9% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 96.019% |
| Waters Corporation | 1.02 Billion USD | 143.924% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 109.75% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 104.158% |
| Biogen Inc. | 2.37 Billion USD | 118.89% |
| Nektar Therapeutics | -243.1 Million USD | -84.698% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -345.33% |
| Perrigo Company plc | 646.2 Million USD | 169.485% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -1104.337% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -910.455% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 244.71% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -413.586% |
| Evolus, Inc. | -41.81 Million USD | -973.937% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 109.647% |
| FibroGen, Inc. | -261.4 Million USD | -71.769% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 126.775% |
| OPKO Health, Inc. | -65.51 Million USD | -585.349% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -96.831% |
| Exelixis, Inc. | 196.6 Million USD | 328.387% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -705.318% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 11.317% |
| Zoetis Inc. | 3.68 Billion USD | 112.185% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -99.569% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -1144.424% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | -95.215% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 514.509% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 199.351% |
| Insmed Incorporated | -654.73 Million USD | 31.421% |
| TG Therapeutics, Inc. | 26.1 Million USD | 1820.356% |
| Incyte Corporation | 919.42 Million USD | 148.836% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 11.139% |